# China Biobanking Market

> China Biobanking Market Research Report: Size, Share, Trend Analysis By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Applications (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End Use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations) and By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.12%
- **2024:** $ 5.28 Billion
- **2025:** $ 5.49 Billion
- **2035:** $ 8.23 Billion
- **Key Players:** Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Biobanking Solutions (NL)

**Report ID:** MRFR/MED/52640-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-biobanking-market-54403

---

## Market Summary

## **China Biobanking Market Overview**

As per MRFR analysis, the China Biobanking Market Size was estimated at 394.4 (USD Million) in 2023. The China Biobanking Market Industry is expected to grow from 411.2(USD Million) in 2024 to 1,020 (USD Million) by 2035. The China Biobanking Market CAGR (growth rate) is expected to be around 8.61% during the forecast period (2025 - 2035).

**Key China Biobanking Market Trends Highlighted**

There are certain big trends in the China Biobanking Market that will change the future. Government efforts to improve the healthcare system are one of the main things driving the industry. These efforts are leading to more research and development. The Chinese government has been pushing biobanking as a key part of precision medicine, which is leading to investments in infrastructure and technology. There is also increasing and more cooperation between private companies and universities to build biobanks that can help with genomics research and tailored medicine. 

As the need for high-quality biospecimens grows among pharmaceutical and biotechnology companies, new opportunities are opening up. As genetic research grows and biobanking technology improve, new collaborations and services become possible. Also, the growing number of older people and the rise in chronic diseases in China are making healthcare professionals use biobanks to better understand and treat these disorders. Recent developments also show that there is more of a focus on following the rules and being ethical when it comes to biobanking. As more people learn about data protection, stakeholders are putting money into open processes to gain trust. 

Also, biobanking activities are clearly moving toward digitalization in order to find better ways to organize and store data.The growing digital health sector in China supports this change by stressing how important it is to combine biobanking with digital technology to get the best research results and better treatment for patients. The overall picture shows that China is committed to using biobanking to improve public health and advance scientific research.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China Biobanking Market Drivers**

**Rising Demand for Customized Medicine**

In China, the push towards personalized and customized medicine is one of the primary drivers of the China Biobanking Market Industry. This trend is driven by advances in genomics and biotechnology, which foster the development of tailor-made treatments based on individual genetic profiles. According to the Ministry of Science and Technology of the People's Republic of China, the nation has seen a 30% increase in genetic testing services over the past five years, reflecting a growing acceptance of personalized medicine among healthcare providers and patients.

Major health organizations, such as the China National Center for Biotechnology Development, are investing significantly in research projects that utilize biobanking to enable the collection of biospecimens essential for developing precision therapies. This surge in demand for personalized healthcare solutions is likely to propel the biobanking sector further.

**Increase in Chronic Diseases and Genetic Disorders**

The prevalence of chronic diseases, such as cancer and diabetes, has been rising in China, creating a robust demand for biobanking services. Recent statistics from the National Health Commission of the People's Republic of China indicate that cancer has become the leading cause of death, with approximately 4.57 million new cases diagnosed annually, and rates are expected to continue increasing. 

This alarming trend drives the need for extensive research and development efforts to understand these diseases better and discover novel treatment options.Consequently, biobanks play a fundamental role in supporting research into population health and disease management, enabling researchers to access a diverse range of biological samples. The growing focus of organizations like the Chinese Cancer Society on cancer research emphasizes the pivotal role that biobanking holds in the fight against these chronic diseases.

**Supportive Government Policies and Investments**

The Chinese government has demonstrated steadfast support for the biobanking sector through favorable policies and significant investments. Initiatives aimed at promoting biotechnology and medical research have spurred growth in the China Biobanking Market Industry. For example, the 'Healthy China 2030' initiative outlines strategic objectives that encourage advancements in healthcare infrastructure, including biobanking facilities. 

Furthermore, the government allocated resources exceeding 200 billion CNY to bolster the biopharmaceutical industry, which includes biobanking as a critical component.Key government-backed institutions, such as the Chinese Academy of Medical Sciences, are actively involved in fostering biobanking initiatives, resulting in enhanced capacity to collect and utilize biosamples for research purposes. This proactive government stance affirms the importance of biobanking in improving public health and catalyzing innovations in healthcare.

**China Biobanking Market Segment Insights**

**Biobanking Market Sample Type Insights**

The Sample Type component of the China Biobanking Market is very important for the growth of healthcare, research, and biotechnology in the area. The government and commercial sector are putting more money into research and development, which is helping this market grow even faster. Blood products are one of the most important types of samples collected since they are used in transfusion treatment and research. This makes them a key part of many biobanks. Tissues, which are also very important, give researchers important information about how diseases progress and are very useful for investigations in regenerative medicine. 

Cells, especially stem cells, are becoming an important source for therapy and personalized medicine, offering possible remedies for diseases that were formerly thought to be impossible to treat. DNA and RNA, which are types of nucleic acids, are becoming more and more important for genetic research and finding biomarkers. They are also very important for precision medicine. Microbiome Samples have also become more popular, which shows that more people want to learn about how the human microbiome affects health and disease.

The variety of sample types shows how different biobanking industries meet varied research goals and trends, making sure they stay useful as new technology and medical demands change.

China's commitment to quality and strict regulatory standards make the samples obtained even more reliable and strong. This sets the stage for new research that improves the health and well-being of the whole population. The increased cooperation between research organizations and academic institutions, which focuses on creating new methods and uses that make the most of the samples, also helps this segment stay active. The Sample Type segment of the China Biobanking Market is therefore a key driver of innovation, closing the gap between fundamental research and real-world, clinical applications that could really change healthcare in the region.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Biobanking Market Application Insights**

The China Biobanking Market is significantly influenced by its Application segment, which plays a crucial role in advancing healthcare and research. Specifically, Research and Development serves as a foundational element, facilitating innovations in drug discovery and genomic studies that benefit from accessing diverse biological samples. Clinical Trials are integral, as they rely heavily on biobanked specimens to evaluate the efficacy and safety of new treatments, ensuring a robust pipeline of therapies. 

Personalized Medicine is gaining prominence, with the increasing emphasis on tailored treatments based on individual genetic profiles, thereby driving demand for biobanks that curate specific biospecimens.Regenerative Medicine is also a vital focus, as it leverages biobanked cells and tissues for therapies aiming to repair or replace damaged tissues and organs. Collectively, these applications highlight the importance of the China Biobanking Market by meeting the rising global demand for precision healthcare and innovative medical solutions. Moreover, advancements in technology and strong governmental support are changing the landscape, presenting vast opportunities for further growth in the region.

**Biobanking Market End Use Insights**

The China Biobanking Market is significantly influenced by its End Use segment, which includes various sectors such as Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations. Academic Research Institutions play a crucial role by utilizing biobanks for advancing scientific knowledge and supporting innovative research projects. Meanwhile, Biotechnology Companies leverage biobanking resources to accelerate product development and enhance their competitive edge in the market. Pharmaceutical Companies benefit from biobanks as they provide essential data and biological materials for drug discovery and development, thereby improving the efficiency of clinical trials.

Government Organizations focus on biobanking to support public health initiatives and regulatory frameworks while ensuring the ethical collection and use of biological samples. The importance of biobanking in China stems from the country’s investment in healthcare advancements and the increasing prevalence of chronic diseases. The growing demand for personalized medicine and the need for large-scale biological data further emphasize the significance of each sector within the End Use category. Collectively, these sectors drive the evolution and expansion of the China Biobanking Market, highlighting the interconnected nature of scientific research, healthcare, and biotechnology in the region.

**Biobanking Market Storage Type Insights**

The Storage Type segment of the China Biobanking Market plays a crucial role in preserving biological samples for research and clinical purposes. Vapor Phase Storage is gaining attention due to its ability to maintain temperature-sensitive materials at precise conditions, ensuring the longevity of samples such as tissues and cells. This method is particularly significant for various medical research applications, enabling advancements in personalized medicine. Liquid Phase Storage is also critical, as it allows for the immediate availability of samples for testing and analysis.

While it presents challenges in terms of energy consumption and operational costs, its ability to maintain a continuous cooling environment is invaluable. Cryopreservation Storage is another vital method that dominates in preserving reproductive cells and embryos, thereby supporting areas such as reproductive health and stem cell therapy. With increasing investments in research initiatives and healthcare in China, the demand for efficient storage solutions continues to rise. Overall, these storage methods contribute significantly to the ongoing development of the China Biobanking Market by ensuring the integrity and accessibility of biological materials essential for scientific advancement.

**China Biobanking Market Key Players and Competitive Insights**

The China Biobanking Market has grown and changed a lot in the last few years. This is because of new developments in biotechnology and genomics, as well as a growing need for biobanks to assist research in personalized medicine, clinical trials, and drug discovery. There is a lot of competition in this sector, with many companies trying to get a firm presence by offering services and capabilities that are different from those of their competitors.

Technological innovation, following the rules, working with research institutes, and being able to keep high standards for collecting, storing, and processing samples are all important elements that affect competition. These things are very important for making sure that biobanking is reliable and ethical. This will draw in researchers and pharmaceutical companies who want to use biobanked specimens for their work. 

Tianjin Jinyao Group is a major player in the China Biobanking Market thanks to its deep knowledge of the biomedical field. The company's operations are supported by cutting-edge technology, like strong preservation methods and state-of-the-art lab facilities, which make sure that biological samples stay safe and used for a long time. This organizational strength is backed up by a strong dedication to research and development, which lets Tianjin Jinyao Group work with academic institutions and medical research facilities all around China.

The company has grown its market presence and built a reputation for reliability and innovation in biobanking solutions through these partnerships. This gives it an advantage over its competitors.

Hua Medicine is another important company in the China Biobanking Market. It is known for offering a wide range of services that meet the demands of researchers and drug firms. The company specializes in biobanking different biological samples that are important for finding and developing new drugs. Its main goal is to improve the availability and quality of these resources. Hua Medicine's market presence is strengthened by its ongoing dedication to cutting-edge research, which has led to the successful deployment of new biobanking techniques.

The company has also made smart mergers and acquisitions to improve its operations and add more services that are specific to the China region. This forward-thinking approach not only makes Hua Medicine more competitive, but it also strengthens its reputation as a trustworthy partner in the biobanking ecosystem, where it provides high-quality, ethically procured biological materials for research and therapeutic use.

**Key Companies in the China Biobanking Market Include:**

- Tianjin Jinyao Group
- Hua Medicine
- Sino Biopharmaceutical
- Huaan Biological Engineering
- Sinovac Biotech
- Fosun Pharma
- Beijing Tiantan Biological Products
- WuXi AppTec
- Shanghai Pharmaceuticals
- Guangdong Haojinghua
- Suzhou Abogen Biosciences
- Changchun BCHT Biotechnology
- Zhejiang Hisun Pharmaceutical
- China National Pharmaceutical Group

**China Biobanking Market Industry Developments**

In recent months, the China Biobanking Market has been witnessing significant developments. Notably, companies like Tianjin Jinyao Group and Hua Medicine have expanded their biobanking capabilities, enabling better access to biological samples for research purposes. The market's growth trajectory is further fueled by a surge in demand for biobanking services, especially in the context of personalized medicine and genomic research, facilitated by players such as Sinovac Biotech and Fosun Pharma. 

Mergers and acquisitions have also made headlines; for instance, in April 2023, WuXi AppTec acquired a controlling stake in Beijing Tiantan Biological Products, enhancing their capabilities in the biobanking sector. This consolidation reflects a broader trend in China, where companies such as Guangdong Haojinghua and Suzhou Abogen Biosciences are repositioning themselves to leverage new opportunities. 

The growth of the biobanking market is supported by favorable government policies and increased investment in Research and Development, with China's National Health Commission showing strong support for biobanking initiatives over the past few years, particularly during announcements in July 2022 regarding funding programs aimed at enhancing biotechnological infrastructure in the country.

**China Biobanking Market Segmentation Insights**

**Biobanking Market Sample Type Outlook**

- Blood Products
- Tissues
- Cells
- Nucleic Acids
- Microbiome Samples

**Biobanking Market Application Outlook**

- Research and Development
- Clinical Trials
- Personalized Medicine
- Regenerative Medicine

**Biobanking Market End Use Outlook**

- Academic Research Institutions
- Biotechnology Companies
- Pharmaceutical Companies
- Government Organizations

**Biobanking Market Storage Type Outlook**

- Vapor Phase Storage
- Liquid Phase Storage
- Cryopreservation Storage

## Market Drivers

### Rising Demand for Personalized Medicine

The increasing focus on personalized medicine in China is driving the biobanking market. As healthcare shifts towards tailored treatments, the need for biobanks to store and manage biological samples becomes crucial. This trend is supported by the Chinese government's initiatives to enhance precision medicine, which is projected to grow at a CAGR of 15% over the next five years. Biobanks play a pivotal role in this landscape, providing essential resources for research and development. The biobanking market is expected to benefit from collaborations between research institutions and healthcare providers, facilitating the integration of biobanked samples into clinical applications. This rising demand for personalized therapies is likely to propel investments in biobanking infrastructure, thereby expanding the market's reach and capabilities.

### Rising Public Interest in Genetic Research

The growing public interest in genetic research is a notable driver for the biobanking market in China. As awareness of genetic disorders and the importance of genetic data increases, more individuals are likely to participate in biobanking initiatives. This trend is reflected in the rising number of genetic testing services and public health campaigns aimed at educating citizens about the benefits of biobanking. The potential for personalized health insights and disease prevention strategies is encouraging participation, which in turn fuels the demand for biobanking services. As public engagement in genetic research grows, biobanks may expand their collections to include diverse populations, enhancing the value of their resources. Thus, the biobanking market is positioned to thrive as public interest in genetic research continues to rise.

### Growing Regulatory Framework for Biobanking

The evolving regulatory framework in China is shaping the biobanking market. Recent policies aimed at standardizing biobanking practices are emerging, which may enhance the quality and reliability of biobanked samples. The establishment of guidelines for ethical sourcing and usage of biological materials is likely to instill greater confidence among researchers and institutions. As compliance with these regulations becomes mandatory, biobanks that adhere to high standards may gain a competitive edge. This regulatory environment could also facilitate international collaborations, as adherence to stringent guidelines may make Chinese biobanks more attractive to global research entities. The biobanking market is thus expected to expand as regulatory clarity fosters trust and encourages investment in biobanking infrastructure.

### Increased Investment in Research and Development

Investment in research and development (R&D) within China is a significant driver for the biobanking market. The Chinese government has allocated substantial funding to enhance biomedical research, with R&D expenditure reaching approximately $300 billion in recent years. This financial commitment fosters the establishment of biobanks that support various research initiatives, including drug discovery and genetic studies. As academic and private institutions seek to leverage biobanked samples for innovative research, the demand for biobanking services is expected to rise. Furthermore, partnerships between biobanks and pharmaceutical companies are likely to flourish, as these entities recognize the value of biobanked materials in accelerating drug development processes. Consequently, the biobanking market is poised for growth, driven by the increasing emphasis on R&D in the healthcare sector.

### Technological Integration in Biobanking Operations

Technological advancements are increasingly influencing the operational efficiency of the biobanking market in China. The integration of automation and data management systems is enhancing sample processing and storage capabilities. Innovations such as artificial intelligence and machine learning are being utilized to optimize sample tracking and analysis, thereby improving the overall efficiency of biobanks. As these technologies become more accessible, biobanks are likely to adopt them to streamline operations and reduce costs. This technological integration not only enhances the quality of biobanked samples but also supports researchers in accessing and utilizing these resources more effectively. Consequently, the biobanking market is expected to experience growth driven by the adoption of advanced technologies that improve operational workflows.

## Future Outlook

The [Biobanking Market](https://www.marketresearchfuture.com/reports/biobanking-market-5967) in China is projected to grow at a 4.12% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased research funding, and rising demand for biobanked samples.

**New opportunities:**

- Development of automated biobanking systems for enhanced sample management efficiency.
- Expansion of partnerships with research institutions for collaborative biobanking initiatives.
- Investment in advanced biobanking technologies for improved sample preservation and analysis.

By 2035, the biobanking market in China is expected to achieve substantial growth and innovation.

## Segment Insights

### By Sample Type: Blood Products (Largest) vs. Tissues (Fastest-Growing)

The 'Sample Type' segment in the China biobanking market reveals that blood products represent the largest portion of market share, indicating a strong preference for these types of samples in storage and research purposes. Tissues, while currently smaller in share, are rapidly gaining traction due to advancements in biobanking technology and increased research initiatives focused on regenerative medicine. 

Growth trends in this segment are notable, with blood products benefiting from established protocols and high demand in clinical applications. Meanwhile, tissues are projected as the fastest-growing category, driven by rising investments in biotechnology, a growing aging population needing regenerative solutions, and a surge in chronic disease prevalence, fostering a comprehensive ecosystem supportive of biobanking practices.

Blood Products (Dominant) vs. Tissues (Emerging)

Blood products have solidified their position as the dominant sample type in the biobanking sector, primarily due to their critical role in transfusions, diagnostics, and various therapeutic applications. They are well-validated, leading to a robust collection and storage framework. In contrast, tissues are emerging as a vital segment, supported by innovations in tissue engineering and regenerative medicine. While blood products see steady demand, tissues respond to a growing call for personalized medicine solutions. The diversification in storage techniques, coupled with research interests, positions tissues as a significant and rapidly evolving area of growth, appealing to modern biobanking needs.

### By Application: Research and Development (Largest) vs. Regenerative Medicine (Fastest-Growing)

The application segment in the China biobanking market reveals a clear distribution of market share among its key values: Research and Development, Clinical Trials, Personalized Medicine, and Regenerative Medicine. Dominating this segment is Research and Development, which holds a significant portion of the market, reflecting the strong emphasis on innovation and advancement in biobanking. Clinical Trials and Personalized Medicine also hold notable shares, however, they fall behind the larger category of Research and Development.

Growth trends indicate that Regenerative Medicine is emerging as the fastest-growing segment within the application category, propelled by advancements in stem cell therapies and tissue engineering. The increasing focus on personalized healthcare and the integration of biobanking in clinical trials further boost the market for these applications. Additionally, the collaboration between various stakeholders, including research institutions and healthcare providers, enhances the growth potential in this dynamic market segment.

Research and Development: Dominant vs. Regenerative Medicine: Emerging

Research and Development is positioned as the dominant force in the application segment, characterized by substantial investments in innovation and a strong pipeline of projects aimed at advancing biobanking technologies. Its substantial influence is evident in numerous clinical outcomes, alongside robust collaborations that enhance research capabilities. On the other hand, Regenerative Medicine is rapidly gaining traction as an emerging segment, largely driven by technological innovations and an increasing need for personalized treatment options. This segment differentiates itself through its focus on creating therapies that restore or replace damaged tissues and organs, thus appealing to the growing demand for tailored medicine and signaling a shift towards more advanced biomedical solutions in the China biobanking market.

### By End-use: Academic Research Institutions (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the China biobanking market, the academic research institutions represent the largest share of market activity, capitalizing on the growing emphasis on research and development in life sciences. This segment benefits from government funding and partnerships with various stakeholders, solidifying its position as a key player. Meanwhile, biotechnology companies are emerging strongly, driven by innovations and advancements in bioprocessing technologies.

The growth trends in this segment are largely influenced by increased investment in biobanking, which is pivotal for various research applications including drug development and personalized medicine. Government organizations play a supportive role by providing regulations that enhance biobanking practices, while pharmaceutical companies leverage biobanks for clinical research. The combination of collaborative academic and industry efforts is setting a robust foundation for future expansion.

Academic Research Institutions (Dominant) vs. Biotechnology Companies (Emerging)

Academic research institutions are at the forefront of the China biobanking market, dominating by establishing extensive biobanking facilities and collaborating with other entities to enhance research outputs. They focus on various applications such as genomics and molecular studies, utilizing biobanks to archive biological samples crucial for analysis. In contrast, biotechnology companies are rapidly emerging as vital contributors to this ecosystem due to their focus on novel therapeutic developments and their adaptability to biobanking requirements. These companies are increasingly integrating advanced analytics and data management into their operations, thereby enhancing their relevance in the market. The dynamic interplay between these two segments fuels innovation and ensures that biobanking continues to thrive in the health and research sectors.

### By Storage Type: Cryopreservation Storage (Largest) vs. Liquid Phase Storage (Fastest-Growing)

In the China biobanking market, the distribution of storage types reveals that Cryopreservation Storage holds the largest market share, primarily due to its established efficacy in preserving biological samples at ultra-low temperatures. Meanwhile, Liquid Phase Storage is emerging rapidly, catering to the growing demand for user-friendly solutions that allow for quick access to biological materials without the complexities involved in vapor phase systems.

The growth trends in the storage type segment are primarily driven by advancements in technology and increasing investments in biobanking facilities. Cryopreservation remains a trusted method; however, Liquid Phase Storage is gaining momentum due to its adaptability and cost-effectiveness. As more biobanks adopt innovative storage solutions, the competition within the market continues to escalate, influencing consumer choices and investments.

Storage Methods: Cryopreservation (Dominant) vs. Liquid Phase (Emerging)

Cryopreservation storage is characterized by its ability to maintain the viability of biological samples over extended periods by utilizing extremely low temperatures, making it a dominant choice among biobanks. This method is essential for the long-term storage of stem cells, reproductive cells, and other critical biological materials. On the other hand, Liquid Phase Storage is regarded as an emerging solution due to its versatility and higher efficiency in accessing samples. It uses liquid nitrogen at moderate temperatures to provide secure storage, enabling rapid retrieval of biological specimens. The increasing preference for Liquid Phase Storage reflects the market's shift towards solutions that offer operational flexibility and cost-effectiveness, thereby enhancing biobanking operations.

### Biobanking Market Storage Type Insights

Biobanking Market Storage Type Insights

The Storage Type segment of the China Biobanking Market plays a crucial role in preserving biological samples for research and clinical purposes. Vapor Phase Storage is gaining attention due to its ability to maintain temperature-sensitive materials at precise conditions, ensuring the longevity of samples such as tissues and cells. This method is particularly significant for various medical research applications, enabling advancements in personalized medicine. Liquid Phase Storage is also critical, as it allows for the immediate availability of samples for testing and analysis.

While it presents challenges in terms of energy consumption and operational costs, its ability to maintain a continuous cooling environment is invaluable. Cryopreservation Storage is another vital method that dominates in preserving reproductive cells and embryos, thereby supporting areas such as reproductive health and stem cell therapy. With increasing investments in research initiatives and healthcare in China, the demand for efficient storage solutions continues to rise. Overall, these storage methods contribute significantly to the ongoing development of the China Biobanking Market by ensuring the integrity and accessibility of biological materials essential for scientific advancement.

## Competitive Benchmarking

The biobanking market exhibits a dynamic competitive landscape, characterized by rapid advancements and strategic maneuvers among key players. Major companies such as Thermo Fisher Scientific (US), Qiagen (DE), and Illumina (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Thermo Fisher Scientific (US) focuses on expanding its product portfolio through technological advancements, while Qiagen (DE) emphasizes regional expansion and collaborations to strengthen its foothold in Asia. Illumina (US) is heavily investing in digital transformation initiatives, which appear to be reshaping the competitive environment by fostering a more integrated approach to biobanking solutions.
The market structure is moderately fragmented, with a mix of established players and emerging companies vying for market share. Key tactics such as localizing manufacturing and optimizing supply chains are prevalent among these companies, allowing them to respond swiftly to regional demands. The collective influence of these players is significant, as they drive innovation and set industry standards, thereby shaping the overall market dynamics.
In September 2025, Thermo Fisher Scientific (US) announced a strategic partnership with a leading Chinese research institution to develop advanced biobanking solutions tailored for local needs. This collaboration is expected to enhance the company's capabilities in providing customized services, thereby solidifying its market presence in China. The strategic importance of this partnership lies in its potential to accelerate product development cycles and improve customer engagement through localized offerings.
In August 2025, Qiagen (DE) launched a new biobanking platform designed to streamline sample collection and storage processes. This initiative is particularly noteworthy as it addresses the growing demand for efficient biobanking solutions in the region. By enhancing operational efficiency, Qiagen aims to capture a larger share of the market, indicating a proactive approach to meeting evolving customer needs.
In October 2025, Illumina (US) unveiled a cutting-edge sequencing technology that integrates artificial intelligence to optimize data analysis in biobanking applications. This technological advancement is poised to revolutionize the way biobanks manage and analyze genetic data, potentially leading to more personalized medicine approaches. The strategic significance of this innovation underscores Illumina's commitment to maintaining its leadership position in the market through continuous technological evolution.
As of November 2025, current trends in the biobanking market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing operational efficiencies. Looking ahead, it appears that competitive differentiation will increasingly pivot from price-based strategies to a focus on innovation, technological advancements, and supply chain reliability, thereby setting the stage for a more resilient and forward-thinking market.

## Recent News & Developments

In recent months, the China Biobanking Market has been witnessing significant developments. Notably, companies like Tianjin Jinyao Group and Hua Medicine have expanded their biobanking capabilities, enabling better access to biological samples for research purposes. The market's growth trajectory is further fueled by a surge in demand for biobanking services, especially in the context of personalized medicine and genomic research, facilitated by players such as Sinovac Biotech and Fosun Pharma. 

Mergers and acquisitions have also made headlines; for instance, in April 2023, WuXi AppTec acquired a controlling stake in Beijing Tiantan Biological Products, enhancing their capabilities in the biobanking sector. This consolidation reflects a broader trend in China, where companies such as Guangdong Haojinghua and Suzhou Abogen Biosciences are repositioning themselves to leverage new opportunities. 

The growth of the biobanking market is supported by favorable government policies and increased investment in Research and Development, with China's National Health Commission showing strong support for biobanking initiatives over the past few years, particularly during announcements in July 2022 regarding funding programs aimed at enhancing biotechnological infrastructure in the country.

## Report Scope

| MARKET SIZE 2024 | 5.28(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 5.49(USD Billion) |
| MARKET SIZE 2035 | 8.23(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.12% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Thermo Fisher Scientific (US), Qiagen (DE), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Biobanking Solutions (NL) |
| Segments Covered | Sample Type, Application, End-use, Storage Type |
| Key Market Opportunities | Advancements in personalized medicine drive demand for biobanking market innovations and regulatory compliance. |
| Key Market Dynamics | Growing demand for personalized medicine drives innovation and competition in the biobanking market. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What was the overall valuation of the China biobanking market in 2024?**
A: The overall market valuation was $5.28 Billion in 2024.

**Q: What is the projected market valuation for the China biobanking market by 2035?**
A: The projected valuation for 2035 is $8.23 Billion.

**Q: What is the expected CAGR for the China biobanking market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 4.12%.

**Q: Which segment had the highest valuation in 2024 within the sample type category?**
A: In 2024, the segment with the highest valuation in the sample type category was Cells, valued at $1.07 Billion.

**Q: What is the projected valuation for the Tissues segment by 2035?**
A: The projected valuation for the Tissues segment by 2035 is $1.58 Billion.

**Q: Which application segment is expected to grow the most by 2035?**
A: The Research and Development application segment is expected to grow the most, reaching $2.48 Billion by 2035.

**Q: What was the valuation of the Pharmaceutical Companies segment in 2024?**
A: The valuation of the Pharmaceutical Companies segment in 2024 was $1.76 Billion.

**Q: What is the projected valuation for Liquid Phase Storage by 2035?**
A: The projected valuation for Liquid Phase Storage by 2035 is $3.25 Billion.

**Q: Which key player is based in the US and is a leader in the biobanking market?**
A: Thermo Fisher Scientific, based in the US, is a key player in the biobanking market.

**Q: What is the expected valuation for the Government Organizations segment by 2035?**
A: The expected valuation for the Government Organizations segment by 2035 is $1.90 Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-biobanking-market-54403*